Hospital
South Peninsula Hospital, INC
South Peninsula Hospital, INC was paid $30.12M by Medicaid between Jan 2018 and Dec 2024, across 172 billing codes. Its largest line is 99284, emergency room visit (serious) — 16% of everything it billed.
33Billing provider infoSOUTH PENINSULA HOSPITAL, INC
HOMER, AK 99603
HOMER, AK 99603
33aNPI1093968372assigned 10/30/2008
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$30.12M
24GClaims314,413
24DCodes billed172
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,558 | $3.14M | |
| 2019 | 40,085 | $4.04M | |
| 2020 | 33,949 | $3.21M | |
| 2021 | 46,323 | $4.31M | |
| 2022 | 52,842 | $5.27M | |
| 2023 | 54,022 | $5.44M | |
| 2024incomplete | 47,634 | $4.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 7,642 | 5,526 | $4.74M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.0% | 2,170 | 1,520 | $2.72M |
| G0378 | Hospital observation service, per hour | 8.9% | 1,527 | 830 | $2.69M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.9% | 6,322 | 5,203 | $2.39M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.4% | 2,244 | 1,775 | $2.22M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 3.0% | 10,897 | 3,279 | $917K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 18,806 | 14,534 | $853K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 1,556 | 1,005 | $833K |
| 80053 | Comprehensive metabolic panel | 2.6% | 16,281 | 12,861 | $798K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 11,236 | 3,374 | $788K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.2% | 13,745 | 6,815 | $667K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.0% | 3,312 | 2,069 | $589K |
160 more codes
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.9% | 2,215 | $557K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.6% | 722 | $479K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 4,390 | $463K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 3,717 | $452K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 4,224 | $442K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 4,617 | $388K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 2,756 | $378K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 3,811 | $317K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,396 | $281K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,163 | $246K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,162 | $213K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,774 | $209K |
| 80305 | <1% | 2,877 | $207K | |
| J3490 | Unclassified drugs | <1% | 5,812 | $205K |
| 84484 | <1% | 3,264 | $202K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 9,912 | $174K |
| 96376 | <1% | 1,372 | $172K | |
| 83735 | <1% | 5,800 | $160K | |
| 84145 | <1% | 2,153 | $152K | |
| 83605 | <1% | 3,216 | $140K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 884 | $132K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,602 | $130K |
| 73562 | <1% | 733 | $128K | |
| 97161 | <1% | 1,116 | $126K | |
| 81001 | <1% | 2,967 | $120K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,096 | $116K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 589 | $115K |
| 83690 | <1% | 2,742 | $107K | |
| 84439 | <1% | 1,652 | $106K | |
| 80061 | Lipid panel | <1% | 2,952 | $104K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 154 | $102K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,076 | $96K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,569 | $96K |
| 87040 | <1% | 1,552 | $95K | |
| 86140 | <1% | 2,884 | $94K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,204 | $93K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 275 | $93K |
| 85730 | <1% | 1,932 | $80K | |
| 83880 | <1% | 867 | $75K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 119 | $65K |
| 85610 | <1% | 2,575 | $61K | |
| 86850 | <1% | 878 | $61K | |
| 81003 | <1% | 4,014 | $61K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,295 | $60K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,928 | $59K |
| 85379 | <1% | 582 | $57K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,433 | $57K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,071 | $56K |
| 82607 | <1% | 1,541 | $55K | |
| 86803 | <1% | 903 | $55K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 293 | $52K |
| 73630 | <1% | 309 | $52K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,164 | $52K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 240 | $48K |
| 84481 | <1% | 732 | $48K | |
| 73030 | <1% | 369 | $47K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 605 | $47K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 40 | $46K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,640 | $46K |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,882 | $44K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,995 | $43K |
| 87186 | <1% | 1,413 | $42K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 340 | $40K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,241 | $39K |
| 84703 | <1% | 1,222 | $39K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 495 | $38K |
| 82728 | <1% | 710 | $36K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,305 | $32K |
| 73610 | <1% | 157 | $30K | |
| 82077 | <1% | 377 | $29K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,897 | $29K |
| A9150 | Non-prescription drugs | <1% | 5,768 | $29K |
| 85651 | <1% | 1,440 | $28K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 95 | $28K |
| 86900 | <1% | 983 | $20K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 47 | $20K |
| 81025 | <1% | 615 | $20K | |
| 87340 | <1% | 425 | $20K | |
| 86901 | <1% | 982 | $20K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,366 | $18K |
| 83540 | <1% | 592 | $18K | |
| 82948 | <1% | 1,923 | $18K | |
| 82803 | <1% | 196 | $14K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 114 | $14K |
| 87070 | <1% | 251 | $14K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 674 | $12K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 864 | $12K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 822 | $11K |
| 87088 | <1% | 391 | $11K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 71 | $10K |
| 83550 | <1% | 498 | $10K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 72 | $10K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,559 | $9K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 545 | $9K |
| 86141 | <1% | 228 | $8K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 705 | $8K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 31 | $8K |
| 86592 | <1% | 305 | $8K | |
| 84403 | <1% | 143 | $8K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 182 | $6K |
| 73110 | <1% | 29 | $6K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 117 | $6K |
| 72110 | <1% | 35 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 215 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 215 | $5K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 244 | $5K |
| 87486 | <1% | 2,037 | $5K | |
| 87581 | <1% | 2,035 | $5K | |
| 82550 | <1% | 128 | $5K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 199 | $5K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 20 | $4K |
| 99442 | <1% | 61 | $3K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 210 | $3K |
| 84144 | <1% | 54 | $3K | |
| 36416 | <1% | 2,000 | $3K | |
| 84702 | <1% | 34 | $3K | |
| 20610 | <1% | 24 | $3K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,163 | $2K |
| 72100 | <1% | 14 | $2K | |
| 96367 | <1% | 32 | $2K | |
| 82670 | <1% | 47 | $2K | |
| 90715 | <1% | 80 | $2K | |
| 82570 | <1% | 86 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 59 | $2K |
| 97116 | <1% | 27 | $2K | |
| 94760 | <1% | 49 | $2K | |
| 86787 | <1% | 48 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 109 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 17 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 155 | $1K |
| 83921 | <1% | 26 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 204 | $1K |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 91 | $1K |
| 87653 | <1% | 14 | $1K | |
| 83001 | <1% | 14 | $1K | |
| 99443 | <1% | 19 | $898.46 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 103 | $879.67 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 93 | $722.92 |
| 86376 | <1% | 15 | $633.60 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 69 | $626.27 |
| 86038 | <1% | 12 | $557.50 | |
| 86308 | <1% | 13 | $525.10 | |
| 86762 | <1% | 16 | $518.81 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 25 | $489.51 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 26 | $362.03 |
| 87077 | <1% | 25 | $349.08 | |
| 82150 | <1% | 12 | $326.54 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 16 | $308.14 |
| 81015 | <1% | 100 | $296.20 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 117 | $270.81 |
| 80320 | <1% | 1,903 | $183.22 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 14 | $180.90 |
| 80329 | 0% | 92 | $0.00 | |
| 0099U | 0% | 39 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 66 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 66 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 29 | $0.00 |
| 91322 | 0% | 16 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 28 | $0.00 |
| 90837 | Psychotherapy session, about an hour | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, RYAN (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Sawgrass Pediatric Dentistry, LLC | Myrtle Beach, SC | $3.56M |
| South Peninsula Hospital, INC. | Homer, AK | $2.72M |
| Ryan Smith Counseling Services, LLC | Kearney, NE | $460K |
| Goodwill Industries of the Chesapeake, INC | Baltimore, MD | $439K |
| Anesthesia SC LLC | Myrtle Beach, SC | $2K |
| West Yellowstone Dental | West Yellowstone, MT | $317.80 |
| Goodwill Indrustries of the Chesapeake, INC | Westminster, MD | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.